Title: ELATIVE Trial: A Landmark Study on Elafibranor’s Efficacy in Primary Biliary Cholangitis Introduction:The medical community has taken a significant step forward with the recent ELATIVE Trial, a study that rigorously evaluates the efficacy and safety of Elafibranor in patients … Read More
Author Archives: admin
CASTLE HTx Trial: Ablation in HF and AFib
The CASTLE HTx trial, as published in the New England Journal of Medicine in 2023, was a single-center, open-label trial that aimed to determine the potential therapeutic effect of catheter ablation for symptomatic atrial fibrillation (AF) in patients with end-stage … Read More
BEAM-BD Trial: Antidepressants in Bipolar 1 Depression
The BEAM-BD trial, as presented in the New England Journal of Medicine in 2023, was a multisite, double-blind, randomized, placebo-controlled trial with the objective of comparing the maintenance of treatment with adjunctive escitalopram or bupropion XL versus discontinuation of antidepressant … Read More
ADVENT Trial: Pulse Field Ablation for AFib
The ADVENT trial, published in the New England Journal of Medicine in 2023, was a randomized, single-blind, noninferiority trial designed to compare the safety and efficacy of pulsed field ablation with conventional thermal ablation techniques (radiofrequency or cryoballoon) for the … Read More
TGC-Fast Trial: Tight Glucose Control in ICU
The TGC-Fast Trial, featured in the New England Journal of Medicine in 2023, was a multicenter, randomized, controlled trial that aimed to assess the benefits of tight glucose control without early parenteral nutrition in the intensive care unit (ICU). The … Read More
Target-HTN trial: Lorundrostat in Hypertension
The TARGET-HTN trial, published in JAMA in September 2023, investigated the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in treating patients with uncontrolled hypertension. This randomized, placebo-controlled, dose-ranging trial included 200 patients who were adults with uncontrolled hypertension … Read More
OCTOBER Trial: OCT in Complex PCI
The OCTOBER trial, detailed in the New England Journal of Medicine in 2023, was a multicenter, randomized, open-label trial designed to assess the effectiveness of optical coherence tomography (OCT) in guiding percutaneous coronary intervention (PCI) for the treatment of complex … Read More
LODESTAR Trial: Statin and CAD
The LODESTAR trial, as featured in JAMA in 2023, was a randomized, multicenter, noninferiority trial focusing on coronary artery disease (CAD) treatment strategies. The objective was to assess whether a treat-to-target strategy for low-density lipoprotein cholesterol (LDL-C) is noninferior to … Read More
HEART-FID Trial: Iron in Heart Failure
The HEART-FID trial, as published in the New England Journal of Medicine in 2023, was a randomized, double-blind, placebo-controlled study designed to determine the efficacy and safety of intravenous ferric carboxymaltose (FCM) in treating patients with heart failure with reduced … Read More
FIRE Trial: Complete PCI in MI in Older Patients
The FIRE trial, published in the New England Journal of Medicine in 2023, was a multicenter, randomized controlled trial that aimed to evaluate the benefits of complete revascularization versus culprit-lesion-only percutaneous coronary intervention (PCI) in older patients (≥75 years of … Read More